Search Results

There are 23380 results for: content related to: Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency

  1. You have free access to this content
    ACR Meeting

    Arthritis & Rheumatism

    Volume 64, Issue S10, October 2012, Pages: S1–S1216,

    Version of Record online : 11 OCT 2012, DOI: 10.1002/art.37735

  2. Adalimumab for treating rheumatoid arthritis

    Intervention Review

    The Cochrane Library

    Federico Navarro-Sarabia, Rafael Ariza-Ariza, Blanca Hernandez-Cruz and Isidro Villanueva

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD005113.pub2

  3. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  4. You have free access to this content
    Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

    Arthritis & Rheumatism

    Volume 64, Issue 12, December 2012, Pages: 3850–3855, Charlotte L. Krieckaert, Anna Jamnitski, Michael T. Nurmohamed, Piet J. Kostense, Maarten Boers and Gertjan Wolbink

    Version of Record online : 28 NOV 2012, DOI: 10.1002/art.34680

  5. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

    British Journal of Dermatology

    Volume 167, Issue 3, September 2012, Pages: 658–667, C. Leonardi, J.M. Sobell, J.J. Crowley, U. Mrowietz, Y. Bao, P.M. Mulani, Y. Gu and M.M. Okun

    Version of Record online : 20 AUG 2012, DOI: 10.1111/j.1365-2133.2012.11041.x

  6. You have free access to this content
    Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 9, November 2014, Pages: 1044–1055, C. Ma, V. Huang, D. K. Fedorak, K. I. Kroeker, L. A. Dieleman, B. P. Halloran and R. N. Fedorak

    Version of Record online : 3 SEP 2014, DOI: 10.1111/apt.12940

  7. Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

    Inflammatory Bowel Diseases

    Volume 17, Issue 1, January 2011, Pages: 127–140, Edward V. Loftus Jr, Scott J. Johnson, Si-Tien Wang, Eric Wu, Parvez M. Mulani and Jingdong Chao

    Version of Record online : 1 JUN 2010, DOI: 10.1002/ibd.21341

  8. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue 8, August 2012, Pages: 991–998, H.-Y. Chiu, T.-S. Wang, C.-Y. Chang and T.-F. Tsai

    Version of Record online : 4 AUG 2011, DOI: 10.1111/j.1468-3083.2011.04199.x

  9. You have free access to this content
    Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 12, June 2010, Pages: 1296–1309, R. PANACCIONE, J.-F. COLOMBEL, W. J. SANDBORN, P. RUTGEERTS, G. R. D’HAENS, A. M. ROBINSON, J. CHAO, P. M. MULANI and P. F. POLLACK

    Version of Record online : 18 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04304.x

  10. You have free access to this content
    Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

    The Journal of Dermatology

    Volume 37, Issue 4, April 2010, Pages: 299–310, Akihiko ASAHINA, Hidemi NAKAGAWA, Takafumi ETOH, Mamitaro OHTSUKI and THE ADALIMUMAB M04-688 STUDY GROUP

    Version of Record online : 26 FEB 2010, DOI: 10.1111/j.1346-8138.2009.00748.x

  11. You have free access to this content
    Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis

    British Journal of Clinical Pharmacology

    Volume 79, Issue 2, February 2015, Pages: 286–297, David Ternant, Emilie Ducourau, Piéra Fuzibet, Céline Vignault, Hervé Watier, Thierry Lequerré, Xavier Le Loët, Olivier Vittecoq, Philippe Goupille, Denis Mulleman and Gilles Paintaud

    Version of Record online : 20 JAN 2015, DOI: 10.1111/bcp.12509

  12. You have full text access to this OnlineOpen article
    A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis

    Arthritis Care & Research

    Volume 67, Issue 11, November 2015, Pages: 1503–1512, Rubén Burgos-Vargas, Shirley M. L. Tse, Gerd Horneff, Aileen L. Pangan, Jasmina Kalabic, Sandra Goss, Kristina Unnebrink and Jaclyn K. Anderson

    Version of Record online : 27 OCT 2015, DOI: 10.1002/acr.22657

  13. You have free access to this content
    Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 11-12, December 2014, Pages: 1324–1332, F. Baert, N. Vande Casteele, S. Tops, M. Noman, G. Van Assche, P. Rutgeerts, A. Gils, S. Vermeire and M. Ferrante

    Version of Record online : 2 OCT 2014, DOI: 10.1111/apt.12968

  14. You have free access to this content
    Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

    Arthritis & Rheumatism

    Volume 50, Issue 5, May 2004, Pages: 1400–1411, Edward C. Keystone, Arthur F. Kavanaugh, John T. Sharp, Hyman Tannenbaum, Ye Hua, Leah S. Teoh, Steven A. Fischkoff and Elliot K. Chartash

    Version of Record online : 6 MAY 2004, DOI: 10.1002/art.20217

  15. Adalimumab safety in global clinical trials of patients with Crohn's disease

    Inflammatory Bowel Diseases

    Volume 15, Issue 9, September 2009, Pages: 1308–1319, Jean-Frédéric Colombel, William J. Sandborn, Remo Panaccione, Anne M. Robinson, Winnie Lau, Ju Li and Alexandra T. Cardoso

    Version of Record online : 11 MAY 2009, DOI: 10.1002/ibd.20956

  16. Adalimumab (Humira)

    Handbook of Therapeutic Antibodies

    Hartmut Kupper, Jochen Salfeld, Daniel Tracey, Joachim R. Kalden, Pages: 696–732, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch27

  17. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 5, May 2013, Pages: 593–600, P.P.M. van Lümig, P.C.M. van de Kerkhof, J.B.M. Boezeman, R.J.B. Driessen and E.M.G.J. de Jong

    Version of Record online : 15 MAR 2012, DOI: 10.1111/j.1468-3083.2012.04496.x

  18. Short-term response to adalimumab in childhood inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 14, Issue 12, December 2008, Pages: 1683–1687, Joshua D. Noe and Marian Pfefferkorn

    Version of Record online : 10 JUL 2008, DOI: 10.1002/ibd.20534

  19. You have free access to this content
    Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

    The Journal of Dermatology

    Volume 42, Issue 11, November 2015, Pages: 1042–1052, Akihiko Asahina, Mamitaro Ohtsuki, Takafumi Etoh, Yihua Gu, Martin M. Okun, Henrique D. Teixeira, Yuji Yamaguchi and Hidemi Nakagawa

    Version of Record online : 29 JUN 2015, DOI: 10.1111/1346-8138.13001

  20. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

    British Journal of Dermatology

    Volume 163, Issue 4, October 2010, Pages: 838–846, P.P.M. Van Lümig, L.L.A. Lecluse, R.J.B. Driessen, P.I. Spuls, J.B. Boezeman, P.C.M. Van De Kerkhof and E.M.G.J. De Jong

    Version of Record online : 22 JUL 2010, DOI: 10.1111/j.1365-2133.2010.09950.x